



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

EPZ011989

Cat. No.:	HY-16986
CAS No.:	1598383-40-4
Molecular Formula:	C ₃₅ H ₅₁ N ₅ O ₄
Molecular Weight:	605.81
Target:	Histone Methyltransferase
Pathway:	Epigenetics
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (165.07 mM; Need ultrasonic)				
		Mass			
		Solvent	1 mg	5 mg	10 mg
		Concentration			
	Preparing Stock Solutions	1 mM	1.6507 mL	8.2534 mL	16.5068 mL
		5 mM	0.3301 mL	1.6507 mL	3.3014 mL
		10 mM	0.1651 mL	0.8253 mL	1.6507 mL
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline				
	Solubility: ≥ 2.5 mg/mL (4.13 mM); Clear solution				
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)				
	Solubility: ≥ 2.5 mg/mL (4.13 mM); Clear solution				
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil				
	Solubility: ≥ 2.5 mg/mL (4.13 mM); Clear solution				

BIOLOGICAL ACTIVITY

Description	EPZ011989 is a potent and orally active Zeste Homolog 2 (EZH2) inhibitor with metabolic stability. EPZ011989 has inhibitory inhibition for EZH2 with a K _i value of <3 nM. EPZ011989 shows robust methyl mark inhibition and anti-tumor activity. EPZ011989 can be used for the research of various cancers ^[1] . EPZ011989 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAC) with molecules containing Azide groups.
IC ₅₀ & Target	EZH2

In Vitro

EPZ011989 inhibits mutant and wild-type EZH2 with an K_i value of <3 nM^[1].
EPZ011989 reduces cellular H3K27 methylation with an IC_{50} value of 94 nM^[1].
EPZ011989 (0-10 μ M; 11 days) has anti-proliferation effect in WSU-DLCL2 cells^[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Proliferation Assay^[1]

Cell Line:	WSU-DLCL2 cells
Concentration:	0-10 μ M
Incubation Time:	11 days
Result:	Demonstrated an average lowest cytotoxic concentration (LCC) in WSU-DLCL2 cells of 208 nM.

In Vivo

EPZ011989 (oral; 30-1000 mg/kg; single or bid; for 7 days or 21 days) can elicit robust methyl mark inhibition and antitumor activity^[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	SCID mice ^[1]
Dosage:	125, 250, 500, and 1000 mg/kg
Administration:	Oral; single, twice-daily (BID) for 7 days or twice-daily (BID) for 21 days
Result:	Provided coverage over the LCC for 24 h (1000 mg/kg), while the 250 and 500 mg/kg doses provided coverage over this value for approximately 8 h. Observed complete ablation of the methyl mark by the end of day 7. Showed robust tumor growth inhibition, methyl mark reduction and extended total and free plasma exposure time.

Animal Model:	Rat ^[1]																																		
Dosage:	30, 100, and 300 mg/kg																																		
Administration:	Oral, single																																		
Result:	<table><tr><th>dose (mg/kg)</th><th>route</th><th>t_{1/2} (h)</th><th>t_{max} (h)</th><th>C_{max} (ng/mL)</th><th>AUC_{inf} (h*ng/mL)</th><th>time above LCC (h)</th></tr><tr><td>30</td><td>p.o.</td><td>4.7</td><td>2</td><td>240</td><td>970</td><td>4</td></tr><tr><td>100</td><td>p.o.</td><td>3.9</td><td>2.7</td><td>1600</td><td>5600</td><td>8</td></tr><tr><td>300</td><td>p.o.</td><td>3.7</td><td>2.7</td><td>2900</td><td>10000</td><td>10</td></tr></table>							dose (mg/kg)	route	t _{1/2} (h)	t _{max} (h)	C _{max} (ng/mL)	AUC _{inf} (h*ng/mL)	time above LCC (h)	30	p.o.	4.7	2	240	970	4	100	p.o.	3.9	2.7	1600	5600	8	300	p.o.	3.7	2.7	2900	10000	10
dose (mg/kg)	route	t _{1/2} (h)	t _{max} (h)	C _{max} (ng/mL)	AUC _{inf} (h*ng/mL)	time above LCC (h)																													
30	p.o.	4.7	2	240	970	4																													
100	p.o.	3.9	2.7	1600	5600	8																													
300	p.o.	3.7	2.7	2900	10000	10																													

CUSTOMER VALIDATION

-
- Proc Natl Acad Sci U S A. 2019 Feb 19;116(8):2961-2966.
 - J Immunother Cancer. 2021 May;9(5):e001335.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Campbell JE, et al. EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity. ACS Med Chem Lett. 2015 Mar 4;6(5):491-495.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA